{"entity":{"id":"paper-andrade-neo-real-adjuvant-safety-2026","kind":"paper","name":"Neo-Real: adjuvant treatment patterns and safety after TNBC chemoimmunotherapy","aka":[],"tldr":"After chemoimmunotherapy, combinations of additional drugs were common when cancer remained at surgery. This study describes safety, not whether the combinations improve survival.","summary":"Brazilian/Argentinian real-world TNBC cohort: 726 included, 692 underwent surgery and safety information was available for 359. Among residual-disease participants without germline BRCA1/2 mutations, most received pembrolizumab/capecitabine; among the small BRCA-mutated residual group, pembrolizumab/olaparib was common. No survival outcomes are reported.","asOf":"2026-10-10","links":[{"label":"Primary publication","url":"https://doi.org/10.1007/s10549-026-07938-0"},{"label":"PubMed record","url":"https://pubmed.ncbi.nlm.nih.gov/41848921/"}],"tags":[],"related":[],"cancers":["breast-cancer","tnbc"],"sections":[],"technologies":[],"targets":["parp"],"drugs":["olaparib","pembrolizumab","capecitabine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"journal":"Breast Cancer Research and Treatment","year":2026,"doi":"10.1007/s10549-026-07938-0","pmid":"41848921","authors":"Andrade MO, Bonadio RC, Ipiña A, et al.","paperType":"real-world","findings":["Pembrolizumab alone had 6.7% grade ≥3 adverse events and lower incidence than combination regimens (p=0.002).","Drug discontinuation: pembrolizumab 5.7%, pembrolizumab/capecitabine 11.2%, pembrolizumab/olaparib 7.7% (p=0.126)."],"whatItMeans":"Observational prescribing/safety data do not establish efficacy, comparative benefit or safety after prior pneumonitis.","caveats":["Observational prescribing/safety data do not establish efficacy, comparative benefit or safety after prior pneumonitis.","Small olaparib-treated subgroup and incomplete safety capture; not evidence for somatic-only adjuvant PARP benefit."],"participants":726},"route":"/key-papers/paper-andrade-neo-real-adjuvant-safety-2026/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}]}}